Final results from the PECATI phase 2 trial position the combination of lenvatinib and pembrolizumab as a potential second-line option for patients with pretreated advanced B3 thymoma and thymic carcinoma, a population with no established standard of care after platinum chemotherapy.
After a median follow-up of 24.6 months, the study reported a median progression-free survival of 22.1 months and a median overall survival of 40.2 months, with a three-year survival rate of 53 percent, according to findings published in the Journal of Thoracic Oncology and reported by EurekAlert and Oncology News Australia.
PECATI trial enrolls pretreated metastatic thymic carcinoma patients
The single-arm, multicenter PECATI trial (NCT04710628) enrolled 43 patients with metastatic B3 thymoma or thymic carcinoma who had progressed after at least one platinum-based regimen, PubMed reported. Patients with pre-existing autoimmune disorders were excluded. Participants received oral lenvatinib 20 mg daily plus intravenous pembrolizumab 200 mg every three weeks for up to 35 cycles or until progression or unacceptable toxicity.
Of the enrolled cohort, 84 percent had thymic carcinoma and 16 percent had B3 thymoma, according to Oncology News Australia. Nearly two-thirds presented with stage IVB disease, more than half had at least three metastatic sites, and approximately 44 percent had received two or more prior lines of therapy for advanced disease.
Efficacy signals exceed early readout
The final analysis builds on an earlier interim report that established the primary endpoint — a five-month PFS rate of 88 percent — and showed a median PFS of 14.9 months, PubMed noted. The mature data nearly doubled that PFS estimate to 22.1 months (95% CI: 10.9–25.1). The confirmed objective response rate was 25.6 percent, including one complete response, while the disease control rate reached 93 percent, Oncology News Australia reported. Median duration of response was not reached.
“ORR of 25.6%, yet an exceptional median PFS of 22.1 months!” wrote Alessio Cortellini, consultant medical oncologist and assistant professor at Campus Bio-Medico University of Rome, on X, as cited by Oncodaily. “Final phase II PECATI results suggest that lenvatinib and pembrolizumab may provide prolonged disease stabilisation beyond objective responses in pretreated advanced thymic tumours.”
Toxicity profile demands vigilant management
Grade 3 or higher treatment-related adverse events occurred in 44.2 percent of patients, leading 27.9 percent to discontinue at least one study drug, according to the PubMed abstract and corroborated by EurekAlert. Immune-related adverse events of any grade appeared in 39.5 percent of participants, including serious cases of colitis, pneumonitis, myocarditis, encephalitis, and liver toxicity, Oncology News Australia detailed. Two grade 5 events (4.7 percent) were deemed unrelated to treatment by investigators.
ORR of 25.6%, yet an exceptional median PFS of 22.1 months! Final phase II PECATI results suggest that lenvatinib + pembrolizumab may provide prolonged disease stabilisation beyond objective responses in pretreated advanced thymic tumours @JTOonline Congrats to @JordiRemon &… pic.twitter.com/r3lo8orB0e
Limitations frame the evidence
Lead investigator Jordi Remon, MD, of the Department of Cancer Medicine at Gustave Roussy in Villejuif, France, cautioned that the study’s relatively small sample size and single-arm design prevent conclusions about superiority over other treatments or the individual contribution of each drug, EurekAlert and Oncology News Australia both reported. The findings support the combination as a potential option for selected patients, with close monitoring for toxicity advised.
Why PFS outpaces response rate in this setting
The disconnect between a modest 25.6 percent response rate and a 22.1-month median PFS suggests the regimen induces durable disease stabilization rather than tumor shrinkage in many patients, a pattern observed with antiangiogenic-immune combinations in other thoracic malignancies. The 93 percent disease control rate reinforces that most patients derived clinical benefit without meeting formal response criteria.
PECATI trial reports median PFS of 22.1 months and 53% three-year OS
| Endpoint | Result |
|---|---|
| Median follow-up | 24.6 months |
| Median PFS | 22.1 months (95% CI: 10.9–25.1) |
| Median OS | 40.2 months (95% CI: 19.1–not estimated) |
| 3-year OS rate | 53.0% |
| Confirmed ORR | 25.6% (1 complete response) |
| Disease control rate | 93% |
| Grade ≥3 TRAEs | 44.2% |
| Discontinuation due to TRAEs | 27.9% |
| Grade 5 events (unrelated) | 4.7% (2 patients) |
PECATI trial answers key questions on thymic carcinoma treatment
What is the current standard second-line treatment for advanced thymic carcinoma?
No standard second-line therapy exists for patients whose cancer progresses after platinum-based chemotherapy, so the PECATI results fill a major treatment gap, according to the trial background on PubMed and EurekAlert.
How does the final PFS compare to the interim analysis?
The final median PFS of 22.1 months substantially exceeds the 14.9 months reported in the earlier analysis, indicating that the benefit was maintained with longer follow-up, PubMed and Oncology News Australia both reported.
Can these results be applied to all thymic epithelial tumors?
The trial specifically enrolled pretreated advanced B3 thymoma and thymic carcinoma; patients with autoimmune disorders were excluded, so generalizability to other histologic subtypes or patient populations remains uncertain, the investigators noted in EurekAlert.
The Journal of Thoracic Oncology, which published the PECATI findings, was established in 2006 as the official journal of the International Association for the Study of Lung Cancer, a global multidisciplinary organization founded in 1974 that now includes more than 11,000 specialists across over 100 countries.
According to a 2026 press release from the association, the journal’s impact factor rose to 23.3 in 2025, ranking it third among respiratory medicine journals and making it the only thoracic oncology sub-specialty journal with an impact factor above 20.
The investigators concluded that the final results of the PECATI trial support the combination of lenvatinib plus pembrolizumab as a potential treatment option in pre-treated advanced B3-thymoma and thymic carcinoma. They said that the toxicity profile is manageable but close monitoring is advised.